Dr. Weber on Emerging Immunotherapy Combinations in Melanoma

Jeffrey S. Weber, MD, PhD
Published: Tuesday, Feb 18, 2020



Jeffrey S. Weber, MD, PhD, deputy director and co-director of the melanoma program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses emerging immunotherapy combinations in melanoma.

The combination of ipilimumab (Yervoy) and nivolumab (Opdivo) is being evaluated in the ongoing phase III CheckMate-915 trial, which enrolled over 1,900 patients with resectable stage IIIB/C/D or stage IV melanoma. Patients will be randomized to receive either the combination or nivolumab alone, says Weber.

Notably, the trial has 2 cohorts of patients: patients with PD-L1–positive tumors and those with PD-L1–negative tumors. The PD-L1–negative cohort was unblinded a couple of months ago; those patients did not benefit from the combination. However, because at least half of the patients enrolled on the trial have PD-L1–positive tumors, the trial will continue, says Weber. The results for this cohort are expected at the end of 2020 or in early 2021, concludes Weber.
SELECTED
LANGUAGE


Jeffrey S. Weber, MD, PhD, deputy director and co-director of the melanoma program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses emerging immunotherapy combinations in melanoma.

The combination of ipilimumab (Yervoy) and nivolumab (Opdivo) is being evaluated in the ongoing phase III CheckMate-915 trial, which enrolled over 1,900 patients with resectable stage IIIB/C/D or stage IV melanoma. Patients will be randomized to receive either the combination or nivolumab alone, says Weber.

Notably, the trial has 2 cohorts of patients: patients with PD-L1–positive tumors and those with PD-L1–negative tumors. The PD-L1–negative cohort was unblinded a couple of months ago; those patients did not benefit from the combination. However, because at least half of the patients enrolled on the trial have PD-L1–positive tumors, the trial will continue, says Weber. The results for this cohort are expected at the end of 2020 or in early 2021, concludes Weber.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x